Dr. Backes on Safety Profile of Lenvatinib and Weekly Paclitaxel in Endometrial Cancer

Dr. Backes on Next Steps for Lenvatinib and Weekly Paclitaxel in Endometrial CancerПодробнее

Evaluating the Benefits of Lenvatinib and Paclitaxel in Recurrent Gynecologic CancersПодробнее

Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial CancerПодробнее

Rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancerПодробнее

Dr. Backes on Rationale for Lenvatinib and Weekly Paclitaxel in Endometrial CancerПодробнее

Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial CancersПодробнее

Dr. Backes on the FILM Trial in Endometrial CancerПодробнее

Dr. Makker on Synergy Between Lenvatinib and Pembrolizumab in Endometrial CancerПодробнее

Dr. Backes on Quality of Life With PARP Inhibitors in Ovarian CancerПодробнее

The common clinical manifestations of BPDCNПодробнее

Dr. Backes Discusses her Experience With PARP Inhibitors in Ovarian CancerПодробнее

Dr. Backes on Treatment Selection With PARP Inhibitors in Ovarian CancerПодробнее

Modest Response Rates in Endometrial CancersПодробнее

Dr. Westin on Remaining Challenges in Endometrial CancerПодробнее

KEYNOTE-775 subgroup analysis in advanced endometrial cancerПодробнее

Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancerПодробнее

Dr. Backes Discusses PARP Inhibitor Combinations in Ovarian CancerПодробнее

Meet Floor Backes, MD—Gynecologic Oncologist at The OSUCCC—JamesПодробнее

Surgery options for gynecologic cancer and the benefits of roboticsПодробнее